BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 35931213)

  • 1. Sirolimus relieves seizures and neuropsychiatric symptoms via changes of microglial polarity in tuberous sclerosis complex model mice.
    Koike-Kumagai M; Fujimoto M; Wataya-Kaneda M
    Neuropharmacology; 2022 Nov; 218():109203. PubMed ID: 35931213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The specificity and role of microglia in epileptogenesis in mouse models of tuberous sclerosis complex.
    Zhang B; Zou J; Han L; Beeler B; Friedman JL; Griffin E; Piao YS; Rensing NR; Wong M
    Epilepsia; 2018 Sep; 59(9):1796-1806. PubMed ID: 30079598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex.
    Zeng LH; Rensing NR; Zhang B; Gutmann DH; Gambello MJ; Wong M
    Hum Mol Genet; 2011 Feb; 20(3):445-54. PubMed ID: 21062901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New insights into the pathogenesis and prevention of tuberous sclerosis-associated neuropsychiatric disorders (TAND).
    Gipson TT; Johnston MV
    F1000Res; 2017; 6():. PubMed ID: 28663780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translatome analysis of tuberous sclerosis complex 1 patient-derived neural progenitor cells reveals rapamycin-dependent and independent alterations.
    Aksoylu IS; Martin P; Robert F; Szkop KJ; Redmond NE; Bhattacharyya S; Wang J; Chen S; Beauchamp RL; Nobeli I; Pelletier J; Larsson O; Ramesh V
    Mol Autism; 2023 Oct; 14(1):39. PubMed ID: 37880800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.
    Zeng LH; Xu L; Gutmann DH; Wong M
    Ann Neurol; 2008 Apr; 63(4):444-53. PubMed ID: 18389497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic pathogenesis of the epileptogenic lesions in Tuberous Sclerosis Complex: Therapeutic targeting of the mTOR pathway.
    Moavero R; Mühlebner A; Luinenburg MJ; Craiu D; Aronica E; Curatolo P
    Epilepsy Behav; 2022 Jun; 131(Pt B):107713. PubMed ID: 33431351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex.
    Theilmann W; Gericke B; Schidlitzki A; Muneeb Anjum SM; Borsdorf S; Harries T; Roberds SL; Aguiar DJ; Brunner D; Leiser SC; Song D; Fabbro D; Hillmann P; Wymann MP; Löscher W
    Neuropharmacology; 2020 Dec; 180():108297. PubMed ID: 32890589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neuropsychiatric manifestations in Tuberous Sclerosis Complex (TSC): diagnostic guidelines, TAND concept and therapy with mTOR inhibitors].
    Waltereit R; Feucht M; de Vries MC; Huemer J; Roessner V; de Vries PJ
    Z Kinder Jugendpsychiatr Psychother; 2019 Mar; 47(2):139-153. PubMed ID: 30080117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebral vascular and blood brain-barrier abnormalities in a mouse model of epilepsy and tuberous sclerosis complex.
    Guo D; Zhang B; Han L; Rensing NR; Wong M
    Epilepsia; 2024 Feb; 65(2):483-496. PubMed ID: 38049961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microglial activation during epileptogenesis in a mouse model of tuberous sclerosis complex.
    Zhang B; Zou J; Han L; Rensing N; Wong M
    Epilepsia; 2016 Aug; 57(8):1317-25. PubMed ID: 27263494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study.
    de Vries PJ; Belousova E; Benedik MP; Carter T; Cottin V; Curatolo P; Dahlin M; D'Amato L; d'Augères GB; Ferreira JC; Feucht M; Fladrowski C; Hertzberg C; Jozwiak S; Kingswood JC; Lawson JA; Macaya A; Marques R; Nabbout R; O'Callaghan F; Qin J; Sander V; Sauter M; Shah S; Takahashi Y; Touraine R; Youroukos S; Zonnenberg B; Jansen AC;
    Orphanet J Rare Dis; 2018 Sep; 13(1):157. PubMed ID: 30201051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Farnesyltransferase Inhibitor Restores Cognitive Deficits in
    Sugiura H; Shimada T; Moriya-Ito K; Goto JI; Fujiwara H; Ishii R; Shitara H; Taya C; Fujii S; Kobayashi T; Hino O; Worley PF; Yamagata K
    J Neurosci; 2022 Mar; 42(12):2598-2612. PubMed ID: 35121635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tuberous sclerosis: a review of the past, present, and future.
    Uysal SP; Şahin M
    Turk J Med Sci; 2020 Nov; 50(SI-2):1665-1676. PubMed ID: 32222129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulation of 6-phosphofructo-2-kinase (PFKFB3) by hyperactivated mammalian target of rapamycin complex 1 is critical for tumor growth in tuberous sclerosis complex.
    Wang Y; Tang S; Wu Y; Wan X; Zhou M; Li H; Zha X
    IUBMB Life; 2020 May; 72(5):965-977. PubMed ID: 31958214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits.
    Feliciano DM; Lin TV; Hartman NW; Bartley CM; Kubera C; Hsieh L; Lafourcade C; O'Keefe RA; Bordey A
    Int J Dev Neurosci; 2013 Nov; 31(7):667-78. PubMed ID: 23485365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. De novo mutation of the TSC2 gene in patient with Tuberous Sclerosis Complex-Associated Neuropsychiatric Disorders (TAND) Phenotype: a case report.
    Triono A; Herini ES; Iskandar K; Hadiyanto ML; Diantika K; Wijayanti VW; Gunadi
    Ann Med Surg (Lond); 2023 May; 85(5):2102-2107. PubMed ID: 37228977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TFEB drives mTORC1 hyperactivation and kidney disease in Tuberous Sclerosis Complex.
    Alesi N; Khabibullin D; Rosenthal DM; Akl EW; Cory PM; Alchoueiry M; Salem S; Daou M; Gibbons WF; Chen JA; Zhang L; Filippakis H; Graciotti L; Miceli C; Monfregola J; Vilardo C; Morroni M; Di Malta C; Napolitano G; Ballabio A; Henske EP
    Nat Commun; 2024 Jan; 15(1):406. PubMed ID: 38195686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation.
    Hwang SK; Lee JH; Yang JE; Lim CS; Lee JA; Lee YS; Lee K; Kaang BK
    Mol Brain; 2016 May; 9(1):56. PubMed ID: 27216612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The TAND checklist: a useful screening tool in children with tuberous sclerosis and neurofibromatosis type 1.
    Cervi F; Saletti V; Turner K; Peron A; Bulgheroni S; Taddei M; La Briola F; Canevini MP; Vignoli A
    Orphanet J Rare Dis; 2020 Sep; 15(1):237. PubMed ID: 32894194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.